GSK701

Translational

-

Human volunteers

GSK

Asexual blood stages

Uncomplicated malaria treatments and resistance management (TPP-1)

Product vision	Uncomplicated malaria treatment and resistance management
MOA	Inhibition of Plasmodium falciparum Acyl-CoA synthetase 10/11
Key features	Novel mode of action and structure Highly potent and active against resistant strains Fast killing in vitro and in vivo Low single dose prediction
Challenges	Low potency on P. vivax and P. knowlesi malaria Limited solubility of crystalline material
Status	First-in-human study completed, induced blood-stage malaria study protocol submitted
Next milestone	Complete phase I programme (including volunteer infection study) Identification of combination partner
Previously	Discovery by GSK with support from the Wellcome Trust Full reference name is MMV1582367
Project Director	Dr Benoît Bestgen